News for Healthier Living

FDA Approves Immune Checkpoint Inhibitor Drug for Patients with Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber Research

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) greater than or equal to 1] as determined by an FDA-approved test.

June 13, 2025


June 27 2025

June 26 2025

June 25 2025

June 24 2025

June 23 2025

June 22 2025

June 21 2025

June 20 2025

June 19 2025

June 18 2025

June 17 2025

June 16 2025

June 15 2025

June 14 2025

June 13 2025